Chelsie Derman

This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.

The FDA has approved remibrutinib, a new oral treatment for chronic spontaneous urticaria, offering hope for patients unresponsive to antihistamines.

A study found 3% hypertonic saline nasal irrigation reduced symptoms in allergic rhinitis but offered no significant advantage over isotonic saline.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

Weeks discusses how tirzepatide is impacting treatment strategies for obstructive sleep apnea and driving collaboration across specialties.

A meta-analysis confirmed CARATkids as a reliable tool for assessing asthma and allergic rhinitis control in children aged 6–12 years.

FDA approval of tirzepatide for OSA sparks a surge in referrals as experts highlight weight loss benefits, symptom relief, and patient selection.

CBT-I improved sleep outcomes and achieved 54% remission in patients with chronic pain, cancer, cardiovascular disease, and other chronic conditions.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

Research suggests emergency department–discharged children rarely return within 7 days, questioning routine corticosteroid use for mild-to-moderate reactions.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

The MACRO study provided no support for long-term clarithromycin use in patients with chronic rhinosinusitis, only supporting endoscopic sinus surgery.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

A study shows children in remission can safely consume peanuts without daily dosing, supporting remission as the primary treatment goal over desensitization.

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

In over 500 patients, a single dose of neffy achieved an 89% success rate, matching injection outcomes and supporting its use as a needle-free alternative.

Fava discusses promising phase 2b trial findings: a single 100 μg dose of MM120 rapidly reduces GAD symptoms by day 2, with benefits lasting 12 weeks.

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

A 30-week trial found weekly semaglutide reduced HbA1c while improving physical quality of life in patients on antipsychotics.

A study shows that sex modifies HRQL outcomes in peanut OIT: males benefit most from active treatment, while females show strong placebo gains.

Cluster protocol VIT demonstrates high efficacy in children with venom allergies, showing low systemic reactions and strong protection against re-stings.

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

Upstream Bio’s VIBRANT trial finds verekitug, a monoclonal antibody binding to the TSLP receptor, reduces nasal polyps in patients with CRSwNP.

This month in review features the top 5 allergy news in August 2025, including FDA approvals, updated guidelines, and emerging research.

FDA approval of weekly subcutaneous lecanemab-irmb offers at-home maintenance therapy for early Alzheimer’s after initial intravenous treatment.

The basophil activation test shows the greatest accuracy in predicting allergic reactions to baked and fresh cow’s milk, reducing the need for oral food challenges in children.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.